Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Liposarcoma × Pioglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Polycystic Ovary Syndrome 5 Insulin Resistance 3 Diabetes Mellitus, Type 2 3 Urinary Bladder Neoplasms 2 Pancreatic Neoplasms 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Carotid Intimal Medial Thickness 1 2 Skin Neoplasms 1 Pharmacokinetics of MDV3100 1 Neoplasm Metastasis 1 Meningioma 1 Memory Disorders 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukoplakia, Oral 1 Leukemia, Myeloid, Chronic-Phase 1 Inflammation 1 Head and Neck Neoplasms 1 Glioblastoma 1 Diabetes Mellitus 1 Cognitive Dysfunction 1 Carcinoma, Squamous Cell 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Doxorubicin 13 Ifosfamide 8 Trabectedin 7 Radiotherapy 7 pazopanib 3 Filgrastim 3 temsirolimus 2 ribociclib 2 pegfilgrastim 2 eribulin 2 cixutumumab 2 brigimadlin 2 belinostat 2 Sunitinib 2 Radiotherapy, Conformal 2 Imatinib Mesylate 2 Gemcitabine 2 Dexamethasone 2 Cyclophosphamide 2 soblidotin 1 sitravatinib 1 siremadlin 1 selinexor 1 sargramostim 1 saracatinib 1 romidepsin 1 ridaforolimus 1 regorafenib 1 perifosine 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04794127 2026-02-18

TRABEPIO

Mario Negri Institute for Pharmacological Research

Phase 2 Completed

Liposarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡